IXICO adds Parkinson's and PET tools to brain imaging platform
Published: 18:10 19 Nov 2026 AEDT
IXICO PLC (LSE:IXI, OTC:PHYOF), the brain imaging analytics company, has signed technology collaborations with Neuropacs and ZRO Imaging to widen the range of tools on its IXI platform.
The deals add a Parkinson's disease algorithm from Neuropacs, a US artificial intelligence software developer, and advanced PET (positron emission tomography) scan analysis from ZRO Imaging, a specialist neuroimaging company.
Neuropacs' algorithm, called AIDP, has received De Novo classification from the US Food and Drug Administration (FDA) as the first diagnostic aid for Parkinsonian syndromes.
It helps clinicians tell Parkinson's disease apart from two similar conditions, multiple system atrophy and progressive supranuclear palsy.
ZRO's tools will strengthen IXICO's PET imaging capabilities in Alzheimer's disease and other neurodegenerative disorders.
IXICO wants IXI to become a one-stop marketplace for neurological imaging biomarkers, the measurable signals in scans that show how a disease is progressing or responding to treatment.
IXI uses machine learning to process brain scans from clinical trials and measure those biomarkers, and IXICO says it carries more than 30 analytics algorithms.
The company has also released an updated version of IXI, with changes to its infrastructure, design and user experience.
IXICO said the update improves operational efficiency and image quality control in clinical trials.
It has also been made more scalable for external commercial use, which IXICO said opens the way to technology licensing, integration and partnerships.
Mark Austin, IXICO's chief technology officer, said the changes would improve the efficiency of its core imaging contract research organisation (iCRO) services while creating opportunities for recurring revenue from licensing and partnerships.
An iCRO analyses scans for drug developers running clinical trials, and IXICO has a 20-year record in the field.
Austin said the aim was to create a "one-stop platform and leading technology destination", expanding the company's addressable market.
IXICO was named Technology Innovation of the Year at the Citeline Biotech Awards 2026 last week.